aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Lusaris Therapeutics, founded with a mission to revolutionize the treatment of severe neuropsychiatric and neurological disorders, focuses on developing next-generation serotonergic neuroplastogen therapeutics. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, designed for rapid action and clearance. Lusaris aims to address unmet medical needs in the neuropsychiatric field through innovative and effective therapeutic solutions.
Notable figures affiliated with Lusaris include leading experts in biotechnology and neuropsychiatry, although specific names are not provided. The company has attracted significant investment from prominent venture capital firms specializing in life sciences. Lusaris's advancements in neuroplastogen therapeutics have the potential to significantly impact the treatment landscape for severe mental health conditions, positioning them as a key player in the biotechnology sector.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Lusaris Therapeutics founded?
Lusaris Therapeutics was founded in 2021.
Where is Lusaris Therapeutics's headquarters located?
Lusaris Therapeutics's headquarters is located in Boston, MA, US.
When was Lusaris Therapeutics's last funding round?
Lusaris Therapeutics's most recent funding round was for $60M (USD) in November 2022.
How many employees does Lusaris Therapeutics have?
Lusaris Therapeutics has 6 employees as of Feb 5, 2024.
How much has Lusaris Therapeutics raised to-date?
As of July 05, 2023, Lusaris Therapeutics has raised a total of $60M (USD) since Nov 2, 2022.
Add Comparison
Total Raised to Date
$60M
USD
Last Update Nov 2, 2022
Last Deal Details
$60M
USD
Nov 2, 2022
Series A
Total Employees Over Time
6
As of Feb 2024
Lusaris Therapeutics Address
200 Berkeley Street
18th Floor
Boston,
Massachusetts
02116
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts